AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06020235
Drug: 10% Nu-3 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
Trial: NCT06020235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel is either applied once per day or twice per day to the infected ulcer.
Trial: NCT06647888
Drug: Envlo Tablet
RxNorm normalized name: ENVIO 30 Day Daily Essentials Duo KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envlo Tab. 0.3mg
Trial: NCT06647888
Drug: Envlomet SR Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envlomet SR Tablet 0.3/ Metformin1,000mg
Trial: NCT06546397
Drug: 17β-estradiol/dydrogesterone tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
Trial: NCT05726916
Drug: Soliris®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab IV administration (900mg/w during 4w then 1200 mg at w5 and 1200mg/2w for 8w) + Blood pressure control with renin angiotensin system blockers
Trial: NCT05726916
Drug: Renin angiotensin system blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure control with renin angiotensin system blockers
Trial: NCT06528262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
Trial: NCT05361421
Drug: Intensive targeting group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid lowering therapy with LDL-cholesterol goal of \<55mg/dL. Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use and ezetimibe or PCSK-9 inhibitor may be considered in patients who could not achieve target LDL-cholesterol level even with the maximum dose of study drugs (atorvastatin 80mg) by the discretion of the investigator.
Trial: NCT05361421
Drug: Conventional therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only moderate intensity statin therapy (atorvastatin 5, 10, and 20mg ) are allowed. Ezetimibe or PCSK-9 inhibitor is not allowed to use.
Trial: NCT05299658
Drug: CNMAu8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
Trial: NCT06416800
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral; Tablet
Trial: NCT06481735
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Trial: NCT03845751
Drug: HIFU hemi-ablation combined with ADT.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
Trial: NCT05151653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06121479
Drug: Branched-chain amino acid
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
Trial: NCT06405776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2μg/kg, granisetron 12mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
Trial: NCT04807972
Drug: modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT05819710
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 5 mg of TS-142
Trial: NCT05819710
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of 10 mg of TS-142
Trial: NCT05819710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of placebo
Trial: NCT05956314
Drug: KM-001 cream 1% 12 weeks treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
Trial: NCT06045481
Drug: administration of single dose of doxycycline
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postexposure prophylaxis with Single Dose doxycycline
Trial: NCT05842395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with distal radius fractures will take daily Placebo orally for three months.
Trial: NCT05072782
Drug: Immunosuppressors (Thiopurines or Methotrexate)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose
Trial: NCT04864418
Drug: AST-021p
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization
Trial: NCT05351021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily for treatment period
Trial: NCT05956314
Drug: KM-001 cream 1% 16 weeks treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
Trial: NCT05026008
Drug: SR1375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
Trial: NCT05026008
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
Trial: NCT04589325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months.
Trial: NCT05636826
Drug: atherolive-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
Trial: NCT05636826
Drug: Placebo Atherolive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
Trial: NCT06441565
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.8 g/m² (400mg bolus + 2.4g/m² continuous infusion) given every 2 weeks through hepatic arterial infusion
Trial: NCT05030324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regardless of the group, all study subjects will receive the standard symptomatic therapy for influenza and other viral URIs, taking into account the latest clinical guidelines (the necessity of symptomatic therapy will be decided by the Investigator).
Trial: NCT05924971
Drug: Aspirin 81Mg Ec Tab
RxNorm normalized name: ASPIRIN 81MG EC TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
Trial: NCT04918576
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL topical of 0.9% normal saline
Trial: NCT05333328
Drug: Ovarian function suppression with endocrine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients.
Trial: NCT06558539
Drug: Standard Medication Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
Trial: NCT06154538
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX chemotherapy
Trial: NCT05096052
Drug: Galactomannan
RxNorm normalized name: Galactomannan Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Trial: NCT05096052
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A blinded matching placebo containing inert chemistry not able to recognise and bind to the galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus
Trial: NCT05377203
Drug: Quadruple combination of half doses therapy→Dual combination of standard dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.
Trial: NCT06252220
Drug: Placebo to DA-1726
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05752305
Drug: MethylPREDNISolone 40 Mg/mL Injectable Suspension
RxNorm normalized name: methylPREDNISolone 40 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative submucosal administration of 8mg of dexamethasone or 40mg of methylprednisolone.
Trial: NCT06226454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT05377203
Drug: Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.
Trial: NCT04433533
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of Rosuvastatin 20mg Monotherapy.
Trial: NCT04433533
Drug: Rosuvamibe 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin10mg/ezetimibe 10mg combination Therapy
Trial: NCT06600022
Drug: SCTB41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTB41 of different doses,IV,every 3 weeks
Trial: NCT06141486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for IV infusion
Trial: NCT06141486
Drug: MRI contrast-enhancing agents
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, as per respective label
Trial: NCT06481553
Drug: first line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel liposome in combination with trastuzumab (or trastuzumab biosimilar, or pyrotinib) ± pertuzumab ± other chemotherapy drugs (such as capecitabine, carboplatin, gemcitabine) may be used for HER-2 positive patients, with the addition of endocrine therapy for triple-positive patients.
Trial: NCT05651022
Drug: Decoy20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
Trial: NCT06044311
Drug: Standard of Care Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy treatment as per standard of care.
Trial: NCT06648304
Drug: TTYP01 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Trial: NCT06648304
Drug: Placebo (Simulant TTYP01 Tablets)
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Trial: NCT05079854
Drug: Intraocular Instillation Solution
RxNorm normalized name: Carbachol Intraocular Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral Moxifloxacin 0.5%
Trial: NCT05055791
Drug: SYHX1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHX1903 tablets, orally, qd
Trial: NCT06484192
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed
Trial: NCT06484192
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants will receive Ketorolac (15 mg) immediately after surgery
Trial: NCT06375343
Drug: PRO-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.
Trial: NCT05749211
Drug: Huaier granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 20 g once, 3 times a day, continued until progression or intolerance of toxicity
Trial: NCT06303921
Drug: 11C-M503 PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
Trial: NCT05699239
Drug: TS-172 10mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of TS-172 10 mg bid
Trial: NCT05394350
Drug: MK-1088
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05699239
Drug: TS-172 30mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of TS-172 30 mg bid
Trial: NCT05699239
Drug: TS-172 60mg bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of TS-172 60 mg bid
Trial: NCT05699239
Drug: TS-172 20mg tid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of TS-172 20 mg tid
Trial: NCT05699239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of placebo
Trial: NCT04524442
Drug: arginine/lysine
RxNorm normalized name: arginine/lysine ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 milliliters (mL) administered at a constant rate of 250 mL per hour
Trial: NCT04486378
Drug: RO7198457 intravenous (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
Trial: NCT06102915
Drug: Nimbex 10 MG in 5 ML Injection
RxNorm normalized name: Nimbex 10 MG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative
Trial: NCT05958277
Drug: Vitamin B3
RxNorm normalized name: VITAMIN B3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B3 upto 16 mg/day
Trial: NCT05355610
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic gentamicin and dexamethasone administered in two doses one week apart
Trial: NCT05142592
Drug: IPG7236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
Trial: NCT06206265
Drug: TRYP-0082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
Trial: NCT06061731
Drug: low-frequency acupoint electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In order to determine the efficacy of low-frequency acupoint electrical stimulation and electroacupuncture to improve thumb to finger action after stroke
Trial: NCT05285644
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular administration of one drop in both eyes BID for 90 days.
Trial: NCT05942053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo match vitamin K2 capsules once per day.
Trial: NCT05942053
Drug: Vitamin K 2
RxNorm normalized name: vitamin K 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
Trial: NCT06654791
Drug: [14C] SIM0270 Oral Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use according to the prescribed protocol